Jubbonti Q Code: Q5136

Drug & Product Overview

HCPCS Descriptor Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg

HCPCS Added Date October 1, 2024

Manufacturer Sandoz

Route of Administration Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About Jubbonti

Jubbonti is a medication aligned to the HCPCS Q Code: Q5136 for billing, pricing, and reimbursement purposes in the United States. It is an Osteoporosis drug administered via the subcutaneous route and manufactured by Sandoz.

According to CMS Drug Use Information: Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause (in women), as you age, if someone in your family has osteoporosis, or if you take certain medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal antibodies. It prevents certain cells in the body (osteoclasts) from breaking down bone. This monograph is about the following denosumab products: denosumab, denosumab-bbdz, denosumab-bmwo, denosumab-bnht, denosumab-desu, denosumab-dssb, denosumab-kyqq, denosumab-nxxp, and denosumab-qbde.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Package	Manufacturer	HCPCS Units	WAC	AWP
61314-0228-94	120 MG / 1.7 ML Wyost Subcutaneous Injection 120 MG/1.7ML - 1 VIAL, SINGLE-DOSE in 1 CARTON (61314-228-94) / 1.7 mL in 1 VIAL, SINGLE-DOSE	Sandoz Inc	120	$3,208.26 $26.736 / unit	$3,849.91 $32.083 / unit
61314-0240-63	60 MG / 1 ML Jubbonti Subcutaneous Injection 60 MG/1ML - 1 SYRINGE in 1 CARTON (61314-240-63) / 1 mL in 1 SYRINGE	Sandoz Inc	60	$1,604.13 $26.736 / unit	$1,924.96 $32.083 / unit

Effective 6/2/25 (WAC & AWP)

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Jubbonti Pricing & Reimbursement

Q5136 Private Payer Reimbursement

$28.97 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

NDC Package

HCPCS Units

Markup / Markdown

%

Common:

Estimates only. Payer reimbursement varies by contract, site of care, and sequestration.

Estimated Reimbursement

Denosumab Biosimilar Information:

Jubbonti Approval Date: March 5, 2024

Product Name	HCPCS Code	Active Ingredient	BLA Type
Prolia	J0897	Denosumab	351(a) Originator Product
Jubbonti and Wyost	Q5136	Denosumab	351(k) Interchangeable
Ospomyv and Xbryk	Q5159	Denosumab	351(k) Interchangeable
Stoboclo and Osenvelt	Q5157	Denosumab	351(k) Interchangeable
Bomyntra and Conexxence	Q5158	Denosumab	351(k) Interchangeable
Bildyos and Bilprevda	Q5162	Denosumab	351(k) Interchangeable
Aukelso and Bosaya	Q5161	Denosumab	351(k) Interchangeable
Enoby and Xtrenbo	Q5167	Denosumab	351(k) Interchangeable
Osvyrti and Jubereq	Q5166	Denosumab	351(k) Interchangeable
Oziltus	Q5165	Denosumab	351(k) Interchangeable
Boncresa	Q5171	Denosumab	351(k) Interchangeable
Ponlimsi	Q5173	Denosumab	351(k) Interchangeable

Jubbonti Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 19.07%

Avg. Days to File 8.2days

Avg. Days to Pay 26.3days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5136 claims analytics on FocalPoint →

Jubbonti CPT Administration Codes

CPT Code	Description
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Jubbonti Medically Unlikely Edits (MUE)

The most billing units of Q5136 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

120 units / day

= 120 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

Jubbonti Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer Giant Cell Tumor of Bone Glucocorticoid-induced osteoporosis Hypercalcemia of Malignancy Multiple Myeloma and Bone Metastasis from Solid Tumors Osteoporosis in men at high risk for fracture Osteoporosis in postmenopausal women at high risk for fracture

Drug Class

RANK Ligand Blocking Activity [MoA]RANK Ligand Inhibitor [EPC]

Frequently Asked Questions

Is there a manufacturer-published billing and coding guide for Jubbonti?

Our team has not identified a manufacturer-published source of billing and coding information for Jubbonti.

Are there any available patient assistance programs for Jubbonti?

Our team has not identified a source of patient assistance information for Jubbonti.

Where can I find Jubbonti prescribing information?

Jubbonti prescribing information can be found at the link below. Visit Here →

Is there available side effect information for Jubbonti?

Side effect information for Jubbonti can be found through Medline Plus at the link below. Visit Here →

Does billing Jubbonti require JZ/JW wastage modifiers?

CMS does not include Jubbonti (Q5136) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5136. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.